Relevant bibliographies by topics / Pancreatic resection

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Books
  4. Book chapters
  5. Conference papers

Academic literature on the topic 'Pancreatic resection'

Author: Grafiati
Published: 4 June 2021
Last updated: 11 March 2023

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Pancreatic resection.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Pancreatic resection"

1

Johnson, C. D. "Palliative Resection of Pancreatic Adenocarcinoma." HPB Surgery 8, no. 3 (January 1, 1995): 181–83. http://dx.doi.org/10.1155/1995/54241.

Full text
Abstract:
A survey was carried out by postal questionnaire of the attitudes of British surgeons to pancreatic resection as palliation for ductal adenocarcinoma of the pancreas. Replies from 24 surgeons related to experience in over 700 resections. The incidence of estimated residual local disease after resection was median 12.5 percent, range 0–35 percent. Half(12) of the surgeons felt that pancreatic resection with residual macroscopic disease was justified. Only 3 (12.5 percent) surgeons accepted that palliative resection in the presence of liver metastases was sometimes justifiable. Further evidence is required of improved quality of life after resection before the majority of surgeons will accept palliative resection in the management of pancreatic ductal adenocarcinoma.
APA, Harvard, Vancouver, ISO, and other styles
2

Bhandare, Manish S., Nikhil Mehta, Vikram Chaudhari, Naveena An Kumar, Esha Pai, Mahesh Goel, and Shailesh V. Shrikhande. "Re-Operative Pancreaticoduodenectomy: Challenges and Outcomes." Digestive Surgery 36, no. 4 (May 23, 2018): 302–8. http://dx.doi.org/10.1159/000489275.

Full text
Abstract:
Background: Tata Memorial Centre (TMC) is a high-volume centre for pancreatic tumour resections. We found a continually increasing referral of pancreatic tumours for re-evaluation for surgery, after an initial unsuccessful attempt at resection. Aim: To evaluate reasons of initial in-operability, the feasibility of re-operative pancreatico-duodenectomy (R-PD) and short- and long-term outcomes after R-PD. Methods: Data was collected from a prospective database of GI and hepato-pancreato-biliary service, TMC, Mumbai from January 2008 to December 2016. Results: Forty patients with periampullary/pancreatic head tumours were referred to us after exploration. Thirty were planned for re-exploration, of whom 25 patients underwent successful R-PD, either upfront (n = 12) or after neo-adjuvant therapy (n = 13). Twenty were adenocarcinomas, 5 had other histologies. Majority of the patients were deemed inoperable in view of suspected vascular involvement at the time of initial surgery (68%). R0 resection was achieved in 90% of adenocarcinoma cases (n = 18). Postoperative major morbidity was 20% and mortality was 4% (n = 1). The estimated 1-, 2- and 5-year survival for those with adenocarcinoma was 83, 71.2, and 29.9% respectively. Conclusion: R-PD is safe and should be performed in experienced centres and can achieve long-term outcomes, comparable to conventional PD. The most common reason for denying resection at initial surgery was suspected or perceived vascular involvement.
APA, Harvard, Vancouver, ISO, and other styles
3

Hegde, Sheetal, Jaswanth Kintada, Miren Peña, Sammira Rouhani, Ali Seifi, Pratap Kumar, and Dimpy Shah. "Disparities in surgical resection for pancreatic cancer stratified by insurance coverage." Journal of Clinical Oncology 36, no. 4_suppl (February 1, 2018): 451. http://dx.doi.org/10.1200/jco.2018.36.4_suppl.451.

Full text
Abstract:
451 Background: Roughly 50,000 Americans are diagnosed with pancreatic cancer yearly (Howlader, N, Noone, A, Krapcho, M. Cancer Stat Facts: Pancreas Cancer. http://seer.cancer.gov/statfacts/html/pancreas ). High mortality rates following pancreatic cancer make surgical resection the primary curative method for treatment. Literature suggests significantly higher mortality rates (12.3%) in patients classified as government payers vs those with private insurance (7.3%) (Glasgow, RE, Mulvihill, SJ (1996)). Hospital volume influences outcome in patients undergoing pancreatic resection for cancer. Western journal of medicine, 165(5),294). This study investigated disparities in use of resection as pancreatic cancer treatment, based on insurance status. Methods: A retrospective study was performed to evaluate use of pancreatic resection (ICD9: 52.51-52.53, 52.59, 52.6, 52.7) vs non-surgical options to treat patients with a principal diagnosis of pancreatic cancer (ICD9: 230.9, 157.1-157.4, 157.8, 157.9) from 2005-2014, using the Healthcare Cost and Utilization Project database. Rates of surgical resection were stratified based on insurance coverage status: private insurance, government insurance, or no insurance. Results: After adjusting for total discharges, we observed that percent pancreatic resections were highest for uninsured populations and lowest for Medicare. By 2014, the rate of surgical resections in uninsured patients decreased as a steady increase was observed for patients with Medicaid. Conclusions: Our preliminary findings suggest that the trends in rates of surgical resection as a treatment for pancreatic cancer vary by insurance status. Further research examining factors such as race, socioeconomic status, and comorbidities that increase the likelihood of uninsured patients receiving pancreatic resections vs other treatments are warranted. [Table: see text]
APA, Harvard, Vancouver, ISO, and other styles
4

Connell, Louise Catherine, Erica Mulvihill, Margaret O'Keeffe, Seamus O'Reilly, Justin Geoghegan, Criostoir O'Suilleabhain, and Derek Gerard Power. "Does age count in pancreatic resection? An Irish experience." Journal of Clinical Oncology 30, no. 4_suppl (February 1, 2012): 348. http://dx.doi.org/10.1200/jco.2012.30.4_suppl.348.

Full text
Abstract:
348 Background: Radical resection offers the only potential cure in pancreas cancer. The majority of patients (pts) are >65 years(yrs) at presentation. Age alone is often a key factor in deciding to resect. The elderly represent 11.5% of the population of Ireland, with an anticipated growth of 26% in the over-65 age group by the end of 2011. Appropriate treatment for elderly potential candidates for pancreatic resection has become increasingly important. We assessed our national experience of pancreatic resection for elderly pts. Methods: Prospectively maintained institutional databases were retrospectively reviewed for all pts undergoing pancreatic resection from 2006 to 2011, in the 2 specialised pancreas cancer centres in Ireland. Demographic, laboratory, treatment and outcome data were obtained and analysed. Results: In a single institution,of the 69 pts who had surgery for pancreas neoplasm, 19 (28%) pts were ≥ 70 yrs. Surgical procedures included pancreaticoduodenectomy (n=16, 84%) and double biliary bypass (n=3,16%). Pathologies included adenocarcinoma (AC) (n=16,84%) and NET (neuroendocrine tumour)/IPMN(intraductal papillary mucinous neoplasms) (n=3, 16%). Number of R0 resections was 15 (15/16,94%). Median baseline ECOG was 1 (range, 0-2).There was no perioperative mortality. Median length of hospital stay was 13 days (range,9-50). Thirteen pts who underwent pancreatico-duodenectomy for AC (81%) received adjuvant chemotherapy (with expected toxicities). Ten pts, after pancreatico-duodenectomy and adjuvant therapy had at least 2 yrs follow-up with median overall survival of 21.5 mths (range,12-44). A further 3 pts aged ≥ 80 yrs underwent pancreaticoduodenectomy followed by adjuvant chemotherapy in the past 12 mths, with no peri-operative complications or significant acute chemotherapy-related toxicities. The data set from the second specialised pancreas cancer centre, with similar survival outcomes, is currently being added to provide overall national results. Conclusions: Age alone should not be a contraindication to pancreatic resection in elderly pts with pancreas cancer. This group can undergo pancreatic resection, with acceptable post-operative morbidity, mortality and overall outcome as evidenced by our national experience.
APA, Harvard, Vancouver, ISO, and other styles
5

Murphy, Melissa M., Jessica P. Simons, Joshua S. Hill, Theodore P. McDade, Sing Chau Ng, Giles F. Whalen, Shimul A. Shah, Lynn H. Harrison, and Jennifer F. Tseng. "Pancreatic resection." Cancer 115, no. 17 (September 1, 2009): 3979–90. http://dx.doi.org/10.1002/cncr.24433.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Schmidt, Thomas, Oliver Strobel, Martin Schneider, Markus K. Diener, Christoph Berchtold, André L. Mihaljevic, Arianeb Mehrabi, Beat P. Müller-Stich, Thilo Hackert, and Markus W. Büchler. "Cavernous transformation of the portal vein in pancreatic cancer surgery—venous bypass graft first." Langenbeck's Archives of Surgery 405, no. 7 (September 11, 2020): 1045–50. http://dx.doi.org/10.1007/s00423-020-01974-0.

Full text
Abstract:
Abstract Background In recent years, several techniques have been introduced to allow safe oncologic resections of cancers of the pancreatic head. While resections of the mesenterico-portal axis became now a part of the routine treatment, patients with a cavernous transformation of the portal vein still pose a surgical challenge and are regularly deemed unresectable. Objective Here, we describe a technique of initial venous bypass graft placement between the superior mesenteric vein or its tributaries and the portal vein before the resection of the pancreatic head. This approach avoids uncontrollable bleeding as well as venous congestion of the intestine with a continuous hepatic perfusion and facilitates oncologic resection of pancreatic head cancers. This technique, in combination with previously published resection strategies, enables tumor resection in locally advanced pancreatic head cancers. Conclusions Venous bypass graft first operations facilitate and enable the resection of the pancreatic head cancers in patients with a cavernous transformation of the portal vein thus rendering these patients resectable.
APA, Harvard, Vancouver, ISO, and other styles
7

Brahmbhatt, Bhaumik, Abhishek Bhurwal, Frank J. Lukens, Mauricia A. Buchanan, John A. Stauffer, and Horacio J. Asbun. "Pancreatic Surgery in the Older Population: A Single Institution’s Experience over Two Decades." Current Gerontology and Geriatrics Research 2016 (2016): 1–6. http://dx.doi.org/10.1155/2016/8052175.

Full text
Abstract:
Objectives. Surgery is the most effective treatment for pancreatic cancer. However, present literature varies on outcomes of curative pancreatic resection in the elderly. The objective of the study was to evaluate age as an independent risk factor for 90-day mortality and complications after pancreatic resection. Methods. Nine hundred twenty-nine consecutive patients underwent 934 pancreatic resections between March 1995 and July 2014 in a tertiary care center. Primary analyses focused on outcomes in terms of 90-day mortality and postoperative complications after pancreatic resection in these two age groups. Results. Even though patients aged 75 years or older had significantly more postoperative morbidities compared with the younger patient group, the age group was not associated with increased risk of 90-day mortality after pancreatic resection. Discussion. The study suggests that age alone should not preclude patients from undergoing curative pancreatic resection.
APA, Harvard, Vancouver, ISO, and other styles
8

Genyk, Yuri, Lea Matsuoka, Anthony B. El-Khoueiry, Syma Iqbal, James Buxbaum, Rick Selby, Jacquez Vandam, and Heinz-Josef Lenz. "R0 resection of locally advanced pancreatic cancer encasing major visceral arteries using arterial reconstruction: Short- and long-term results." Journal of Clinical Oncology 30, no. 15_suppl (May 20, 2012): e14679-e14679. http://dx.doi.org/10.1200/jco.2012.30.15_suppl.e14679.

Full text
Abstract:
e14679 Background: Locally advanced disease is found in about 40% of patients with pancreatic cancer at initial presentation. Tumors involving major visceral arteries are commonly deemed unresectable. In this study we analyzed the feasibility of R0 resection of locally advanced pancreatic cancer encasing major visceral arteries using arterial reconstruction. Methods: The following data were collected: age, gender, operative details, post-operative complications, chemotherapy and/or radiation therapy and overall and disease free survival. Patient survival was calculated utilizing Kaplan-Meier survival probability estimates. Results: From Dec., 2002 to Jan., 2012, 13 patients underwent pancreatic resection with concomitant resection and reconstruction of major visceral arteries for pancreatic cancer (9 males and 4 females, median age 63 yrs (range: 50–82 yrs)). The arterial involvement included celiac artery (n=6), superior mesenteric artery (n=4) and hepatic artery (n=3). Resections included pancreatico-duodenectomy (n=9), distal pancreatectomy (n=3), and total pancreatectomy (n=1). Management of the arterial involvement included: resection of celiac axis without reconstruction (n=2), reconstruction of one artery (n=6), two arteries (n=4) and three arteries (n=1). Nine of the 13 patients underwent simultaneous venous reconstruction. R0 resection was accomplished in 11, R1 in 1, and R2 in 1 patient. Ten of the 13 patients received neoadjuvant and/or adjuvant chemo- or chemo-radiation therapy outside protocols. To date, 4 patients are alive and disease free at 1, 4, 15 and 111 months, and 1 patient is alive with recurrence at 100 months. Six-month patient survival was 65% and median overall survival was 17 months. The probability of 5-year survival was 22%. Conclusions: Our study indicates that in select patients with locally advanced pancreatic cancer with involvement of major visceral arteries R0 resection is feasible by performing pancreatic resection with arterial reconstruction. The survival data in this group of patients are encouraging and provide the opportunity to reconsider the contraindications to surgical management of such patients.
APA, Harvard, Vancouver, ISO, and other styles
9

Bachmann, Jeannine, Christoph W. Michalski, Marc E. Martignoni, Markus W. Büchler, and Helmut Friess. "Pancreatic resection for pancreatic cancer." HPB 8, no. 5 (October 2006): 346–51. http://dx.doi.org/10.1080/13651820600803981.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Jordan, George L. "Pancreatic Resection for Pancreatic Cancer." Surgical Clinics of North America 69, no. 3 (June 1989): 569–97. http://dx.doi.org/10.1016/s0039-6109(16)44836-x.

Full text
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Pancreatic resection"

1

Wiltberger, Georg, Julian Nikolaus Bucher, Felix Krenzien, Christian Benzing, Georgi Atanasov, Moritz Schmelzle, Hans-Michael Hau, and Michael Bartels. "Extended resection in pancreatic metastases." Universitätsbibliothek Leipzig, 2016. http://nbn-resolving.de/urn:nbn:de:bsz:15-qucosa-206265.

Full text
Abstract:
Background: Metastases to the pancreas are rare, accounting for less then 2 % of all pancreatic malignancies. However, both the benefit of extended tumor resection and the ideal oncological approach have not been established for such cases; therefore, we evaluated patients with metastasis to the pancreas who underwent pancreatic resection. Methods: Between 1994 and 2012, 676 patients underwent pancreatic surgery in our institution. We retrospectively reviewed patients’ medical records according to survival, and surgical and non-surgical complications. Student’s t-test and the log-rank test were used for statistical analysis. Results: Eighteen patients (2.7 %) received resection for pancreatic metastases (12 multivisceral resections and 6 standard resections). The pancreatic metastases originated from renal cell carcinoma (n = 10), malignant melanoma (n = 2), neuroendocrine tumor of the ileum (n = 1), sarcoma (n = 1), colon cancer (n = 1), gallbladder cancer (n = 1), gastrointestinal stromal tumor (n = 1), and non-small cell lung cancer (n = 1). The median time between primary malignancy resection to metastasectomy was 83 months (range, 0–228 months). Minor surgical complications (Grade I-IIIa) occurred in six patients (33.3 %) whereas major surgical complications (Grade IIIb-V) occurred in three patients (16.6 %). No patients died during hospitalization. The median follow-up was 76 months (range, 10–165 months). One-year, 3-year and 5-year survival for standard resection versus multivisceral resection was 83, 50, and 56 % versus 83, 66, and 50, respectively. Twelve patients died after a median of 26 months (range, 5–55 months). Conclusions: A surgical approach with curative intent is justified in select patients suffering from metastases to the pancreas and offers good long-term survival. The resection of pancreatic metastases of different tumor types was associated with favorable morbidity and mortality when compared with resection of the primary pancreatic malignancies. Our findings also demonstrated that multivisceral resection was feasible, with acceptable long term outcomes, even though morbidity rates tended to be higher after multivisceral resection than after standard resection.
APA, Harvard, Vancouver, ISO, and other styles
2

Distler, Marius, Felix Rückert, Maximilian Hunger, Stephan Kersting, Christian Pilarsky, Hans-Detlev Saeger, and Robert Grützmann. "Evaluation of survival in patients after pancreatic head resection for ductal adenocarcinoma." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2013. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-127053.

Full text
Abstract:
Background: Surgery remains the only curative option for the treatment of pancreatic adenocarcinoma (PDAC). The goal of this study was to investigate the clinical outcome and prognostic factors in patients after resection for ductal adenocarcinoma of the pancreatic head. Methods: The data from 195 patients who underwent pancreatic head resection for PDAC between 1993 and 2011 in our center were retrospectively analyzed. The prognostic factors for survival after operation were evaluated using multivariate analysis. Results: The head resection surgeries included 69.7% pylorus-preserving pancreatoduodenectomies (PPPD) and 30.3% standard Kausch-Whipple pancreatoduodenectomies (Whipple). The overall mortality after pancreatoduodenectomy (PD) was 4.1%, and the overall morbidity was 42%. The actuarial 3- and 5-year survival rates were 31.5% (95% CI, 25.04%-39.6%) and 11.86% (95% CI, 7.38%-19.0%), respectively. Univariate analyses demonstrated that elevated CEA (p = 0.002) and elevated CA 19–9 (p = 0.026) levels, tumor grade (p = 0.001) and hard texture of the pancreatic gland (p = 0.017) were significant predictors of a poor survival. However, only CEA >3 ng/ml (p < 0.005) and tumor grade 3 (p = 0.027) were validated as significant predictors of survival in multivariate analysis. Conclusions: Our results suggest that tumor marker levels and tumor grade are significant predictors of poor survival for patients with pancreatic head cancer. Furthermore, hard texture of the pancreatic gland appears to be associated with poor survival.
APA, Harvard, Vancouver, ISO, and other styles
3

Jomrich, Gerd, Elisabeth S. Gruber, Daniel Winkler, Marlene Hollenstein, Michael Gnant, Klaus Sahora, and Martin Schindl. "Systemic Immune-Inflammation Index (SII) Predicts Poor Survival in Pancreatic Cancer Patients Undergoing Resection." Springer US, 2019. http://dx.doi.org/10.1007/s11605-019-04187-z.

Full text
Abstract:
Background: The systemic immune-inflammation index based on peripheral neutrophil, lymphocyte, and platelet counts has shown a prognostic impact in several malignancies. The aim of this study was to determine the prognostic role of systemic immune-inflammation index in patients with pancreatic ductal adenocarcinoma undergoing resection. Methods: Consecutive patients who underwent surgical resection at the department of surgery at the Medical University of Vienna between 1995 and 2014 were included into this study. The systemic immune-inflammation index was calculated by the formula platelet*neutrophil/lymphocyte. Optimal cutoffs were determined using Youden's index. Uni-and multivariate analyses were calculated by the Cox proportional hazard regression model for overall survival. Results Three hundred twenty-one patients were included in this study. Clinical data was achieved from a prospective patient database. In univariate survival analysis, elevated systemic immune-inflammation index was found to be significantly associated with shortened patients' overall survival (p = 0.007). In multivariate survival analysis, systemic immune-inflammation index remained an independent prognostic factor for overall survival (p = 0.004). No statistical significance could be found for platelet to lymphocyte ratio and neutrophil to lymphocyte ratio in multivariate analysis. Furthermore, area under the curve analysis showed a higher prognostic significance for systemic immune-inflammation index, compared to platelet to lymphocyte ratio and neutrophil to lymphocyte ratio. Conclusion A high systemic immune-inflammation index is an independent, preoperative available prognostic factor in patients with resectable pancreatic ductal adenocarcinoma and is superior to platelet to lymphocyte ratio and neutrophil to lymphocyte ratio for predicting overall survival in pancreatic ductal adenocarcinoma patients.
APA, Harvard, Vancouver, ISO, and other styles
4

Echrish, Hussein H. Jassim. "Effect of resection of localised pancreatic cancer on tissue-factor promoted pathways of thrombosis, cell invasion and angiogenesis." Thesis, University of Hull, 2011. http://hydra.hull.ac.uk/resources/hull:5375.

Full text
Abstract:
Pancreatic (PC) is the eleventh most common malignancy in the UK but it has the poorest prognosis of all human adenocarcinoma. The autopsy, epidemiological and clinical studies have consistently identified PC as one of the most highly angiogenic and invasive malignancies, with the greatest prevalence and incidence of thrombo-embolism (TE). The incidence of TE in PC has been reported as high as 57%. Tissue factor (TF) bearing microparticles (MP) have recently been shown to promote thrombosis. The biological link between cancer haemostasis, cell invasion and angiogenesis remains unclear. These three indices may be driven by PC cells directly, be a reflection of the individual tumour stromal microenvironment and/or a result of the inflammatory response of the host. The hypothesis of the thesis is that factors directly attributed to the cancer promote the observed pathophysiology and that the removal of the tumour should result in reversal of these abnormalities. Flow cytometry was used for the evaluation of MP in plasma and quantification of surface-expressed TF, VEGFR-1 and-2 and EGFR. Cellular TF activity and pro-coagulant activity (prothrombin time) of PC patients were measured using a coagulometer. Matrigel Invasion Chambers and Boyden chambers with collagen IV were used to measure cellular invasion. A two dimensional angiogenesis assay was used to evaluate tubule formation in vitro in response to PC sera. Relative levels of protein expression of 55 angiogenic markers in the sera of PC patients were evaluated using a human angiogenesis array kit. Enzyme-linked immunosorbent assay was undertaken on VEGF, TF, TFPI, Leptin and annexin autoantibodies using sera or plasma from PC patients as appropriate. Immunohistochemical analysis of key markers of angiogenesis and thrombosis was also undertaken on resected PC samples. The in vitro optimisation experiments revealed that the cell invasion was significantly correlated with TF antigen expression and activity on PC cell lines (MIA-PaCa-2, AsPC-1 and CFPAC1) and that blocking TF on these cells decreased cell invasion. In the same manner neutralising soluble TF in PC serum samples also significantly decreased cell invasion, as did spiking of the serum with low molecular weight heparin. Analysis of sera from patients showed that TF bearing MP, pro-coagulant activity, cell invasion and angiogenesis (total length and number of capillaries) of PC cases were significantly higher than the control. Furthermore, the post-operative median number of TF bearing MP, procoagulant activity, cell invasion and angiogenesis (total length and total number of capillaries) were all significantly lower compared with pre-operative samples. Out of 55 angiogenic markers studied in 6 PC patients, pre- and post-operatively there was a significant decrease of angiopoietin-1, angiostatin/plasminogen, PDGF-AA, PDGF-AB/PDGF-BB and VEGF post-operatively. This result was supported by ELISA analysis of 29 samples and 14 controls that also showed significantly higher levels of VEGF in pancreatic cancer sera versus control groups, and that there was a significant decrease observed post-operatively only in the cancer patients. Furthermore both angiogenesis array and ELISA showed increased leptin levels post-operatively. Immunohistochemical analysis of the pancreatic tissue sections revealed that TF was expressed on 62 % of PC samples. There was significant correlation between TF expression on the tissue and procoagulant activity. Also, there was a significant correlation between tissue-expressed TF and in vitro angiogenesis, i.e. total length and number of capillaries. Furthermore, there was a significant correlation between TF expression on tissue with intratumoural microvascular density (MVD) and tumour-expressed with VEGFR 2. As expected, high levels of MVD correlated with high levels of tissue-expressed VEGF. Finally serum from patients who showed a high level of tissue-expressed VEGF also induced the greatest level of in vitro angiogenesis, i.e. number of capillaries. In summary, it was shown that TF expression on cell lines was significantly correlated with TF activity and cell invasion, and that TF expression in plasma and on tissue from PC patients was significantly correlated with procoagulant activity, cell invasion and angiogenesis. PC tissue-expressed VEGF was significantly associated with the angiogenic activity of PC sera and tissue MVD. Thus, the pathophysiology represented by a high procoagulant state, elevated cell invasion and angiogenic properties seen in PC patient sera appears to be driven by the malignant cells, as removal of the tumour causes a return towards the normal state.
APA, Harvard, Vancouver, ISO, and other styles
5

Wahib, Ramez [Verfasser], and Dean [Akademischer Betreuer] Bogoevski. "Overall survival after pancreatectomy with en bloc portal vein resection for macroscopically infiltrating pancreatic cancer / Ramez Wahib ; Betreuer: Dean Bogoevski." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2019. http://d-nb.info/1200101898/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Wahib, Ramez Verfasser], and Dean [Akademischer Betreuer] [Bogoevski. "Overall survival after pancreatectomy with en bloc portal vein resection for macroscopically infiltrating pancreatic cancer / Ramez Wahib ; Betreuer: Dean Bogoevski." Hamburg : Staats- und Universitätsbibliothek Hamburg, 2019. http://nbn-resolving.de/urn:nbn:de:gbv:18-101193.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Betzler, Alexander, Soeren Torge Mees, Josefine Pump, Sebastian Schölch, Carolin Zimmermann, Daniela E. Aust, Jürgen Weitz, Thilo Welsch, and Marius Distler. "Clinical impact of duodenal pancreatic heterotopia – Is there a need for surgical treatment?" Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2017. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-227082.

Full text
Abstract:
Background Pancreatic heterotopia (PH) is defined as ectopic pancreatic tissue outside the normal pancreas and its vasculature and duct system. Most frequently, PH is detected incidentally by histopathological examination. The aim of the present study was to analyze a large single-center series of duodenal PH with respect to the clinical presentation. Methods A prospective pancreatic database was retrospectively analyzed for cases of PH of the duodenum. All pancreatic and duodenal resections performed between January 2000 and October 2015 were included and screened for histopathologically proven duodenal PH. PH was classified according to Heinrich’s classification (Type I acini, ducts, and islet cells; Type II acini and ducts; Type III only ducts). Results A total of 1274 pancreatic and duodenal resections were performed within the study period, and 67 cases of PH (5.3%) were identified. The respective patients were predominantly male (72%) and either underwent pancreatoduodenectomy (n = 60); a limited pancreas resection with partial duodenal resection (n = 4); distal pancreatectomy with partial duodenal resection (n = 1); total pancreatectomy (n = 1); or enucleation (n = 1). Whereas 65 patients (83.5%) were asymptomatic, 11 patients (18.4%) presented with symptoms related to PH (most frequently with abdominal pain [72%] and duodenal obstruction [55%]). Of those, seven patients (63.6%) had chronic pancreatitis in the heterotopic pancreas. The risk of malignant transformation into adenocarcinoma was 2.9%. Conclusions PH is found in approximately 5% of pancreatic or duodenal resections and is generally asymptomatic. Chronic pancreatitis is not uncommon in heterotopic pancreatic tissue, and even there is a risk of malignant transformation. PH should be considered for the differential diagnosis of duodenal lesions and surgery should be considered, especially in symptomatic cases.
APA, Harvard, Vancouver, ISO, and other styles
8

Goonetilleke, Kolitha Sanjaya. "Pancreatic cancer in the twenty-first century : national overview of management and detailed assessment of patients undegoing resection by anthropometric and biological marker studies." Thesis, University of Manchester, 2009. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.509843.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Gomes, dos Santos Ferreira Rebelo Artur Luis [Verfasser], Jörg H. [Gutachter] Kleeff, Patrick [Gutachter] Michl, and André Leopold [Gutachter] Mihaljevic. "Systematic review and meta-analysis of arterial resection in pancreatic surgery / Artur Luis Gomes dos Santos Ferreira Rebelo ; Gutachter: Jörg H. Kleeff, Patrick Michl, André Leopold Mihaljevic." Halle (Saale) : Universitäts- und Landesbibliothek Sachsen-Anhalt, 2020. http://d-nb.info/1218075678/34.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Volk, Andreas, Stephan Kersting, Ralf Konopke, Frank Dobrowolski, Stefan Franzen, Detlef Ockert, Robert Grützmann, Hans Detlev Saeger, and Hendrik Bergert. "Surgical Therapy of Intrapancreatic Metastasis from Renal Cell Carcinoma." Saechsische Landesbibliothek- Staats- und Universitaetsbibliothek Dresden, 2014. http://nbn-resolving.de/urn:nbn:de:bsz:14-qucosa-136489.

Full text
Abstract:
Background: Pancreatic métastases from renal cell carcinoma (RCC) are clinically rare but highly resectable. The aim of this article is to identify patients who profit from pancreatic resection of RCC despite the invasiveness of the surgery. Methods: Between January 1996 and December 2007, data from 744 patients were collected in a prospective pancreatic surgery database, and patients with metastasis into the pancreas from RCC were identified. Results: Resective surgery was performed in 14 patients with metastasis to the pancreas from RCC. Most patients were clinically asymptomatic. The median interval between primary treatment of RCC and occurrence of pancreatic metastasis was 94 months (range 32–158). The morbidity rate was 42.8%. Patients with a metastasis size <2.5 cm had a much better survival after resection (100 months) than those with a metastasis size >2.5 cm (44 months). Moreover, the number of métastases predicts the survival after resection. Conclusions: In patients with pancreatic métastases from RCC who have only limited disease, complete resection of all lesions can be successfully performed with a low rate of complications. Thus, patients with a history of RCC should be monitored for more than 10 years after nephrectomy to detect recurrence
Dieser Beitrag ist mit Zustimmung des Rechteinhabers aufgrund einer (DFG-geförderten) Allianz- bzw. Nationallizenz frei zugänglich
APA, Harvard, Vancouver, ISO, and other styles
More sources

Books on the topic "Pancreatic resection"

1

Wellner, Ulrich. Locally advanced pancreatic head cancer – margin-positive resection or bypass? Freiburg: Universität, 2012.

Find full text
APA, Harvard, Vancouver, ISO, and other styles
2

Agarwal, Anil, Neil Borley, and Greg McLatchie. Hepato-pancreato-biliary (HPB) surgery. Oxford University Press, 2017. http://dx.doi.org/10.1093/med/9780199608911.003.0003.

Full text
Abstract:
This chapter on hepato-pancreato-biliary surgery covers the endoscopic retrograde cholangio pancreatogram (ERCP), liver resection, pancreatico-duodenectomy (Whipple’s procedure), and necrosectomy. Steps of surgery for chronic pancreatitis are mentioned, as are the procedures that are carried out for this condition.
APA, Harvard, Vancouver, ISO, and other styles
3

Prasad, Raj K., and Imeshi Wijetunga. Hepatobiliary surgery (DRAFT). Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198749813.003.0002.

Full text
Abstract:
This chapter discusses common elective and emergency presentations to hepatobiliary surgery. Gallstone disease, being the commonest hepatobiliary condition encountered by general surgical trainees, is discussed in detail. A separate section on acute ascending cholangitis is included with a brief description of the steps involved in laparoscopic cholecystectomy. Acute pancreatitis is discussed in Pancreatic Surgery Chapter 3. An overview of the assessment and management of post-cholecystectomy complications, such as bile duct injury and vascular injuries, is provided with illustrations. Management of common malignant conditions of the liver, such as colorectal liver metastasis, hepatocellular carcinoma, and cholangiocarcinoma, is included with detailed discussion of pre-operative imaging. Liver resection surgery and liver transplant surgery, as well as non-surgical management, are discussed. Details of post-operative management of hepatobiliary patients are aimed at the junior surgical trainee working in a tertiary hepatobiliary unit to aid day-to-day management of post-operative patients on the wards, as well as subsequent follow-up.
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Pancreatic resection"

1

Tee, May C., and Michael B. Farnell. "Major Pancreatic Resection." In The Pancreas, 467–78. Chichester, UK: John Wiley & Sons, Ltd, 2018. http://dx.doi.org/10.1002/9781119188421.ch59.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Pisters, Peter W. T., Jeffrey E. Lee, and Douglas B. Evans. "Standard Forms of Pancreatic Resection." In Pancreatic Cancer, 181–99. Totowa, NJ: Humana Press, 1998. http://dx.doi.org/10.1007/978-1-4612-1810-4_10.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Cooper, M. J. "Resection of the Pancreatic Head." In Pancreatic Disease, 137–49. London: Springer London, 1991. http://dx.doi.org/10.1007/978-1-4471-3356-8_12.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Rahbari, Nuh N., Nathan Mollberg, Moritz Koch, John P. Neoptolemos, Jürgen Weitz, and Markus W. Büchler. "Surgical Resection for Pancreatic Cancer." In Pancreatic Cancer, 971–96. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-77498-5_39.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dunne, Declan F. J., Jörg Kleeff, Vincent S. Yip, Christopher Halloran, Paula Ghaneh, and John P. Neoptolemos. "Arterial Resection in Pancreatic Cancer." In Pancreatic Cancer, 1089–104. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7193-0_72.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Al-Refaie, Waddah B., and Jeffrey E. Lee. "Vascular Resection for Pancreatic Cancer." In Pancreatic Cancer, 351–63. Boston, MA: Springer US, 2008. http://dx.doi.org/10.1007/978-0-387-69252-4_20.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dunne, Declan F. J., Jörg Kleeff, Vincent S. Yip, Christopher Halloran, Paula Ghaneh, and John P. Neoptolemos. "Arterial Resection in Pancreatic Cancer." In Pancreatic Cancer, 1–16. New York, NY: Springer New York, 2016. http://dx.doi.org/10.1007/978-1-4939-6631-8_72-1.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Nimura, Yuji. "Venous Resection in Pancreatic Cancer Surgery." In Pancreatic Cancer, 997–1013. New York, NY: Springer New York, 2010. http://dx.doi.org/10.1007/978-0-387-77498-5_40.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Bassi, C., M. Falconi, S. Pedrazzoli, C. Pasquali, and P. Pederzoli. "Resection in Cancer: Lymph Node Dissection." In Pancreatic Disease, 397–407. London: Springer London, 1999. http://dx.doi.org/10.1007/978-1-4471-0801-6_36.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Yokoyama, Yukihiro, and Yuji Nimura. "Venous Resection in Pancreatic Cancer Surgery." In Pancreatic Cancer, 941–65. New York, NY: Springer New York, 2018. http://dx.doi.org/10.1007/978-1-4939-7193-0_40.

Full text
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Pancreatic resection"

1

Wiltberger, G., M. den Dulk, A. Andert, J. Bednarsch, Z. Czigany, S. Lang, F. Ulmer, and U. Neumann. "Perioperative Outcome of en-bloc arterial resection in pancreatic surgery." In Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1733603.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Wiltberger, G., M. den Dulk, A. Andert, J. Bednarsch, Z. Czigany, S. Lang, F. Ulmer, and U. Neumann. "Perioperative Outcome of en-bloc arterial resection in pancreatic surgery." In Viszeralmedizin 2021 Gemeinsame Jahrestagung Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Sektion Endoskopie der DGVS, Deutsche Gesellschaft für Allgemein und Viszeralchirurgie (DGAV). Georg Thieme Verlag KG, 2021. http://dx.doi.org/10.1055/s-0041-1733603.

Full text
APA, Harvard, Vancouver, ISO, and other styles
3

Ibrahimov, Emin, Nhu-An Pham, Fannong Meng, Mayleen Sukhram, Dianne Chadwick, Stefano Serra, Patricia Shaw, et al. "Abstract B91: Primary tumor xenograft establishment from pancreatic resection specimens." In Abstracts: AACR Special Conference on Pancreatic Cancer: Progress and Challenges; June 18-21, 2012; Lake Tahoe, NV. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.panca2012-b91.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Safi, SA, A. Rehders, WT Knoefel, and A. Krieg. "Standardized radical resection for pancreatic head cancer does improve local control." In Viszeralmedizin 2019. Georg Thieme Verlag KG, 2019. http://dx.doi.org/10.1055/s-0039-1695226.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

Dudgeon, Crissy, Jeffrey Rosenfeld, Eric Collisson, and Darren Carpizo. "Abstract B14: The expression landscape of pancreatic cancer recurrence following resection." In Abstracts: AACR Special Conference on Tumor Metastasis; November 30-December 3, 2015; Austin, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.tummet15-b14.

Full text
APA, Harvard, Vancouver, ISO, and other styles
6

Dudgeon, Crissy, Jeffrey Rosenfeld, Eric Collisson, and Darren Carpizo. "Abstract PR13: The expression landscape of pancreatic cancer recurrence following resection." In Abstracts: AACR Special Conference on Tumor Metastasis; November 30-December 3, 2015; Austin, TX. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.tummet15-pr13.

Full text
APA, Harvard, Vancouver, ISO, and other styles
7

Dudgeon, Crissy, Jeffrey Rosenfeld, Matthew Habel, Eric Collisson, and Darren Carpizo. "Abstract LB-351: The expression landscape of pancreatic cancer recurrence following resection." In Proceedings: AACR 107th Annual Meeting 2016; April 16-20, 2016; New Orleans, LA. American Association for Cancer Research, 2016. http://dx.doi.org/10.1158/1538-7445.am2016-lb-351.

Full text
APA, Harvard, Vancouver, ISO, and other styles
8

Grant, Robert C., Kai Duan, Richard Jackson, William Greenhalf, Eithne Costello-Goldring, Paula Ghaneh, Christopher Halloran, et al. "Abstract PO-005: GATA6 expression is prognostic after surgical resection of pancreatic cancer: results from the ESPAC trials." In Abstracts: AACR Virtual Special Conference on Pancreatic Cancer; September 29-30, 2020. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/1538-7445.panca20-po-005.

Full text
APA, Harvard, Vancouver, ISO, and other styles
9

Raimo, Cristina A. Metildi, Sharmeela Kaushal, Chanae R. Hardamon, Cynthia S. Snyder, Robert M. Hoffman, and Michael Bouvet. "Abstract 375: Fluorescence-guided surgery leads to improved resection of primary pancreatic cancer and prolonged survival." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-375.

Full text
APA, Harvard, Vancouver, ISO, and other styles
10

Pinney, Emmett, Rhiana Menen, Mohamed Hassanein, Mayra Montes-Camacho, Gail Naughton, Michael Bouvet, and Robert M. Hoffman. "Abstract 2676: A secreted tissue engineered extracellular matrix (shECM) prevents recurrence in post-resection pancreatic cancer models." In Proceedings: AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-2676.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Pancreatic resection' for particular source types:
Journal articles Dissertations / Theses
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography